Hosted on MSN8h
Sudden Ascent: Is Recursion Pharmaceuticals NVIDIA's AI Favorite?
CompanyOverview|NASDAQ:RXRX] Recursion Pharmaceuticals' (NASDAQ: RXRX) stock price has seen a dramatic increase, not due to ...
Dealbreaker on MSN1d
Recursion Pharma Accelerator Steps In to Fill Some of the Funding Gap Amid NIH Tumult
Altitude Lab Fund will provide pre-seed funding for early-stage startups affected by changes to grant programs administered ...
Recursion Pharmaceuticals Needs A Clinical Breakthrough To Pique Interest
Recursion Pharmaceuticals struggles with validation of REC-994 and competition in oncology. Read why RXRX stock is a hold ...
pharmaphorum1d
Recursion, Exscientia, and AI drug discovery’s moment of truth
“Our platforms at Recursion really focused on application of biology, hit discovery, target discovery,” he said. “We've been building that for over a decade and our colleagues at Exscientia ...
Altitude Lab Startups Raise $154M in Capital
Today, Altitude Lab announced that its incubating startups have collectively raised $154 million in early-stage funding since its launch in 2020. Founded by Recursion, Altitude Lab supports diverse ...
The Motley Fool7d
Why Recursion Pharmaceuticals Stock Is Soaring Today
Nvidia exited its positions in several AI stocks in Q4, but maintained its stake in Recursion Pharmaceuticals. Many investors seemed to view this as a vote of confidence from Nvidia for Recursion.
Nasdaq7d
Why Recursion Pharmaceuticals Stock Is Soaring Today
Shares of Recursion Pharmaceuticals (NASDAQ: RXRX) had soared by 15.8% as of 12:06 p.m. ET on Friday. Did the clinical-stage biotech company report great news? Nope. Instead, the stock's gains ...